Erythropoietin Administration for Anemia Due to Chronic Kidney Disease - Subcutaneous OR Intravenous, What Do We Know So Far?

The prevalence of anemia in chronic kidney disease (CKD) patients is almost twice that of the normal population and its severity increases exponentially as the disease worsens, dramatically affecting the quality of an individual’s life. The advent of erythropoiesis stimulating agents (ESA) in the 19...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahab, Muhammad Hasan, Saifullah Khan, Shahzeen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549864/
https://www.ncbi.nlm.nih.gov/pubmed/33062481
http://dx.doi.org/10.7759/cureus.10358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549864/
https://www.ncbi.nlm.nih.gov/pubmed/33062481
http://dx.doi.org/10.7759/cureus.10358

Ejemplares similares